Emergency Use Authorization of the World’s First Plasmid DNA COVID-19 Vaccine Delivered Exclusively with the PharmaJet Needle-free Injection System
In August 2021, Zydus Cadila received Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world’s first plasmid DNA Vaccine for COVID-19. The vaccine, for those 12 years and above, is exclusively administered using the PharmaJet Tropis® Needle-free Injection System. Plans are moving forward to manufacture 80+ million doses of the ZyCoV-D vaccine in South Korea to be exported to several lower-middle income countries in Latin America and Asia.
COVID-19 Pre-Clinical Studies and Clinical Trials
Pre-Clinical Studies
DNA (12)
RNA (2)
Multiple (1)
Phase 1 Clinical Studies
DNA (6)
- BioNet Asia COVIGEN
- DIOSynVax
- Scancell COVIDITY
RNA (1)
Phase 2 Clinical Studies
DNA (1)
- Nykode VB D-01
Phase 3 Clinical Studies
DNA (1)
- Zydus Cadila ZyCoV-D
COVID-19 Vaccine Partnerships
Click on image to enlarge